The biotechnology recovery is not a farce. These 3 stocks could lead the next bullish leg
The stock market's attention has been focused almost exclusively on artificial intelligence, semiconductors and a handful of large-cap technology companies.…
health care industry
Cramer Says This Stock Is Significantly Undervalued And Sees 35% Upside
Every weekday, CNBC's Investment Club with Jim Cramer hosts a livestream “morning meeting” at 10:20 a.m. ET. Here's a recap…
Employers Are Not Expanding Coverage of GLP-1 Anti-Obesity Drugs: Survey
A version of this article first appeared in CNBC's Healthy Returns newsletter, bringing the latest healthcare news directly to your…
AstraZeneca trial failure raises bigger questions about its portfolio
AstraZenecaWainua's failed final trial was never expected to have a major financial impact on the company. Most analysts estimate that…
Abivax receives $920 million in cash to prepare for US launch: CEO
AbivaxThe latest round of funding allows the biotech to move toward launching its intestinal disease drug in the United States…
AstraZeneca shares fall 9% after heart drug trial falls short of target
Actions of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug failed to…
Jim Cramer Says These Are the 5 Stocks to Buy During This Market Rotation
CNBC's Jim Cramer said Monday that investors should not fear the latest market rotation. Instead, he believes he is creating…
Experts say USAID shutdown made virus harder to contain
Doctors Without Borders health workers in personal protective equipment move through the isolated red zone to monitor patients, provide medical…
FDA allows Philip Morris-owned Zyn to be marketed as less harmful cigarettes
The Food and Drug Administration on Tuesday authorized Philip MorrisZyn's proprietary Zyn nicotine pouches will be marketed as less harmful…
Jim Cramer Says This Former Covid Market Favorite May Finally Be Invested Again
modern Expanding the portfolio beyond infectious diseases is giving investors a new reason to own stocks after years of uncertainty…